ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed.
- Single-cell and spatial RNA sequencing in prostate cancer.Nature reviews. Urology · 2026Review
- Bipolar androgen therapy as platform for personalized medicine in castration-resistant prostate cancer.Discover oncology · 2026Article
- Systems-level liquid biopsy in advanced prostate cancer.Endocrine-related cancer · 2025Review
- Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies.Research and reports in urology · 2025Review
- Co-evolution ofNAR cancer · 2023Article
- Second generation androgen receptor antagonists and challenges in prostate cancer treatment.Cell death & disease · 2022Review
- Review
- Circulating Tumor Cells and TWIST Expression in Patients with Metastatic Gastric Cancer: A Preliminary Study.Journal of clinical medicine · 2021Article
- Review
- Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability.Cells · 2021Review
- Review
- Tracking cancer progression: from circulating tumor cells to metastasis.Genome medicine · 2020Review
- Long Non-Coding RNA DARS-AS1 Contributes to Prostate Cancer Progression Through Regulating the MicroRNA-628-5p/MTDH Axis.Cancer management and research · 2020Article
- The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?Prostate cancer · 2020Review
- Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2019Article
- Recent advances in microfluidic methods in cancer liquid biopsy.Biomicrofluidics · 2019Review
- Detection of CTC Clusters and a Dedifferentiated RNA-Expression Survival Signature in Prostate Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Liquid Biopsy in Oligometastatic Prostate Cancer-A Biologist's Point of View.Frontiers in oncology · 2019Review
- Circulating tumor cells in genitourinary tumors.Therapeutic advances in urology · 2018Review
- Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer.Frontiers in oncology · 2018Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo assess the feasibility of characterizing gene copy number alteration by fluorescence in situ hybridization (FISH) of circulating tumor cells (CTC) isolated using the CellSearch system in patients with progressive castration-resistant metastatic prostate cancer. EXPERIMENTAL
designWe used probe combinations that included the androgen receptor (AR) and MYC genes for FISH analysis of CTC samples collected from 77 men with castration-resistant metastatic prostate cancer.
resultsHigh-level chromosomal amplification of AR was detected in 38% and relative gain of MYC in 56% of samples analyzed. No such abnormalities were detected in samples with CTC counts of <10, reflecting ascertainment difficulty in these lower count samples.
conclusionThe CTC isolated from our patient cohort present a very similar molecular cytogenetic profile to that reported for late-stage tumors and show that FISH analysis of CTC can be a valuable, noninvasive surrogate for routine tumor profiling. That as many as 50% of these patients have substantial amplification of the AR locus indicates that androgen signaling continues to play an important role in late-stage prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.